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H
ypertrophic cardiomyopathy (HCM) is a condition characterized by otherwise unexplained left ventricular (LV) hypertrophy and in adults is most commonly associated with mutations in genes coding for sarcomere proteins. 1, 2 In children, HCM peak incidence is during the first year of life. 3 Population-based pediatric cardiomyopathy registries from Australia (the National Australian Childhood Cardiomyopathy Study [NACCS] ) 4 and the North American Pediatric Cardiomyopathy Registry 5 have confirmed the high early mortality noted in single-center reviews. [6] [7] [8] [9] Additionally, the North American Pediatric Cardiomyopathy Registry study has identified disease-specific risk factors and outcomes. 10 In children, HCM may be progressive and may not reach maximal phenotypic expression until the second or third decade. The late survival and symptomatic status for children with HCM have not been well defined. In this study, we describe the long-term outcomes and explore risk factors for death or transplantation in children with HCM enrolled in a national population-based study.
METHODS
The data that support the findings of this study are available from the corresponding author on reasonable request.
The NACCS is a longitudinal cohort study maintained as a registry of all children 0 to 10 years of age who were diagnosed with primary cardiomyopathy in Australia between January 1, 1987 , and December 31, 1996. Institutional review board approval was obtained from each participating center. Enrollment of consecutive patients proceeded after a single pediatric cardiologist (R.G.W.) reviewed and reinterpreted all relevant investigations, including cardiac imaging. Cardiomyopathy diagnosis and case classification at enrollment in NACCS were performed according to World Health Organization criteria. 11 Inclusion criteria for this study were all patients diagnosed with hypertrophic cardiomyopathy at <10 years of age in the study period. Subjects with metabolic, storage, and neuromuscular diseases were excluded. The methodology from the NACCS has been described previously. 3 Before determination of long-term follow-up, subjects enrolled in NACCS at diagnosis (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) were reevaluated according to current HCM diagnostic criteria. 2 In brief, HCM was defined by septal or LV free wall hypertrophy (z score >2 for either) in the absence of systemic hypertension or structural heart disease. Although routine genetic testing was not available at the time of the study, Noonan syndrome was clinically diagnosed by multidisciplinary genetics review when typical phenotypic features were present. Subjects with an affected first-or second-degree relative were considered to have familial HCM. Signs and symptoms of congestive heart failure (CHF) were recorded by the attending physician if present.
Prospective clinical and echocardiographic follow-up was arranged for all surviving subjects. Collection of clinical and epidemiological data for each enrolled subject was obtained from inpatient and outpatient records, including the results of relevant investigations during follow-up. Serial echocardiographic measurements of LV dimensions, septal and posterior wall thickness, and fractional shortening were expressed as z scores based on body surface area (or age in the case of fractional shortening). 12, 13 These echocardiographic parameters were routinely quantified in all subjects who underwent echocardiography at diagnosis, at 3-month intervals during the first year and then at yearly intervals until latest followup. The annual rate of change in LV fractional shortening or wall thickness z score was estimated using linear regression of echocardiographic data available in successive 2-year windows, with an estimate carried forward if echocardiographic data were absent in a subsequent interval. HCM was further defined as symmetrical LV hypertrophy if both the LV free wall and interventricular septum were affected to a similar degree or as asymmetrical septal hypertrophy if the interventricular septum was disproportionately involved. LV outflow tract obstruction was defined as anatomic subaortic narrowing, together with a measured systolic gradient at cardiac catheterization or an estimated peak instantaneous gradient of ≥15 mm Hg from echocardiography. 
Statistical Analysis
Time-to-event analysis was used to estimate rates of the combined end point of death or cardiac transplantation, censoring patient follow-up time at time of last contact. The end points of death and transplantation were considered equivalent for the NACCS cohort because heart
Clinical Perspective
What Is New?
• The National Australian Childhood Cardiomyopathy Study is a long-term national cohort study, with a median follow-up duration of 15 years among surviving subjects.
• The greatest risk of death or transplantation for children with hypertrophic cardiomyopathy is in the first year after diagnosis, with 14% of study subjects achieving this combined end point, compared with 0.4% per year thereafter.
• Risk factors for death or transplantation include symmetrical left ventricular hypertrophy at diagnosis, Noonan syndrome, increasing left ventricular free wall thickness, and lower fractional shortening during follow-up.
• The majority of surviving subjects have no symptoms.
What Are the Clinical Implications?
• This population-based study identifies long-term outcomes and risk factors in children with hypertrophic cardiomyopathy.
• Children with hypertrophic cardiomyopathy who are alive 1 year after diagnosis have low long-term rates of death or transplantation.
• Deaths from congestive heart failure usually occur soon after diagnosis, whereas the risk of sudden cardiac death is ongoing.
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ORIGINAL RESEARCH ARTICLE transplantation was not widely available in the early part of the study, and the number of patients who died greatly exceeded those who underwent cardiac transplantation. Surgery during follow-up was not registered as a censoring event in the analysis. Survival time to death or cardiac transplantation was estimated using the Kaplan-Meier method and is reported as estimates of the proportion surviving transplant-free with 95% confidence intervals (CIs) at 1, 10, and 20 years after diagnosis. Analysis of potential prognostic factors for the combined end point of death or transplantation was undertaken using Cox proportional hazards modeling with a Firth correction. Univariate analysis of important clinical characteristics was performed. Stepwise regression that included measures with a univariate P value of ≤0.25 was used to build 2 multivariable models: (1) a model containing only variables known at baseline (ie, at presentation with cardiomyopathy) and (2) a model using time-dependent (serial) echocardiographic z scores for posterior wall thickness, fractional shortening, and interventricular septal thickness as candidate predictors. Results are presented as hazard ratios (HRs), 95% CIs, and 2-sided P values. Analysis was performed using Stata 14 software 14 and SAS version 9.4 (SAS Institute, Inc).
RESULTS
A total of 80 patients with HCM were identified during the study enrollment period, representing 25.5% of the NACCS study population. All patients enrolled in NACCS with HCM according to the initial World Health Organization criteria 11 continued to meet current diagnostic criteria for HCM. 2 No patients were lost to follow-up. The clinical characteristics and outcomes of the study population are shown in Table 1 . The median age at diagnosis was 0.48 years (interquartile range [IQR] 0.1, 2.5 years), with 49 patients (61%) presenting during the first year of life. Signs and symptoms of CHF at the time of diagnosis were present in 6 (8%) of patients, all of whom had preserved systolic function. Patients with familial HCM were diagnosed at a median of 1.7 years (IQR, 0.49-5.80 years) and those with no family history at a median of 0.35 years (IQR, 0.04-1.72 years). The median follow-up time was 14 years (IQR 10.7, 17.1 years), extending to a median of almost 16 years (IQR 12.9, 17.7 years) for transplantfree surviving subjects.
Time to Death or Transplantation
A total of 17 subjects (21%) reached the combined end point of death or cardiac transplantation during followup, with 16 deaths and 1 cardiac transplant. 
Risk Factors and Cause of Death or Transplantation
The results of univariate analysis of risk factors for the combined end point of death or cardiac transplantation are presented in Table 2 . Survival of patients according to Noonan syndrome diagnosis is shown in Figure 2A . There was a trend toward better survival in those with a positive family history (P=0.08), and there were no deaths or transplantations in this group (Figure 2B ). There were only 2 patients with consanguinity, (Table 3) .
The most common causes of death comprised CHF in 7 subjects (all with preserved LV systolic function), sudden cardiac death (SCD) in 4 subjects, and sepsis in 2 subjects. Deaths from CHF tended to occur early, with median time from diagnosis to death of 0.6 years (range, 0.1-8.2), whereas SCD occurred more evenly during follow-up (median, 7.3 years; range 0.2-13.8).
LV Outflow Tract Obstruction and Late Symptoms
LV outflow tract obstruction was documented at diagnosis or during follow-up in 43 (54%) subjects. The presence of LV outflow tract obstruction was unrelated to survival. Surgical relief of LV outflow obstruction was undertaken in 19 subjects on the basis of symptoms (most commonly exercise intolerance) or a large outflow gradient that persisted despite medical therapy. Fifteen (78.9%) of these subjects remain alive at follow-up.
There were 4 patients who died after surgical myectomy. One infant with heart failure and biventricular outflow obstruction who underwent myectomy remained in severe heart failure and was wait-listed for heart transplantation but died 6 months postoperatively. The other 3 deaths were 6.4, 7.8, and 13.7 years postoperative and were considered unrelated to surgery.
At latest follow-up, 33 of the 63 transplant-free surviving patients (53%) are symptom-free and receiving no medication. Of the 63 surviving patients, 27 (42%) are being treated with a β-blocker, and 13 (21%) have had an implantable cardioverter-defibrillator (ICD) placed. Seven ICDs were placed for primary prevention and 6 for secondary prevention. Appropriate ICD discharges were documented in 3 of 10 subjects with ICDs, for whom this information was available. At latest review, there were 9 subjects (14% of survivors) who reported some degree of exercise limitation, all of whom are receiving medical therapy. The remaining surviving patients (54 of 63, 86%) did not report cardiac symptoms.
DISCUSSION
Multicenter registry studies have informed the risk factors for early mortality associated with childhood HCM; however, long-term survival and symptomatic status remain ill defined. 2, 9, 10 The NACCS registry represents a complete longitudinal cohort of children with cardiomyopathy diagnosed during the study period, for whom the median follow-up among surviving subjects is now >15 years. 15, 16 Completeness of subject enrollment, consistency of data collection, and case classification were ensured by having the same observers visit each contributing center, with a single observer reviewing all available diagnostic material. 3 Prospective follow-up of this cohort now provides important insights into the long-term outcomes of childhood HCM. 
Survival and Risk Factors for Death or Transplantation
Our study shows that occurrence of death and cardiac transplantation in pediatric HCM reduce dramatically 1 year after diagnosis, from 14% during this initial high-risk period to ≈0.4% per subsequent year of follow-up. Markers of LV hypertrophy, notably symmetrical left LV hypertrophy at diagnosis and increasing LV posterior wall thickness during follow-up, were related to increasing rates of death or transplantation, as were minor reductions in LV systolic function. Congestive heart failure, which was responsible for the majority of early deaths, was likely associated with significant diastolic dysfunction, although this could not be quantified from serial echocardiograms. LV outflow obstruction was unrelated to outcome, although surgical intervention in the form of myectomy in this group was common. In our study, transplant-free survival was similar at 10 and 20 years (80% and 78%, respectively), demonstrating a low risk of death from CHF and arrhythmias during late follow-up. This finding may reflect a favorable natural history for children surviving the first year or possibly the multiple interventions applied to this patient group. At latest follow-up, almost half of subjects were being treated with medication, but the majority (86%) of subjects did not report cardiac symptoms.
Specific risk factors for death or transplantation regularly identified in pediatric populations comprise increasing LV posterior wall thickness 4,9,10 and CHF. 5, 7, 10, 17 Risk stratification within the North American Pediatric Cardiomyopathy Registry cohort was enhanced by the use of multiple risk factors, including younger age at diagnosis, presence of CHF, and echocardiographic findings of lower LV fractional shortening or higher LV posterior wall thickness. 10 Patients with Noonan syndrome were also found to have poorer survival than patients without this diagnosis because of a worse risk profile at presentation. 18 In our study, Noonan syndrome, a higher posterior wall thickness z score, and a lower fractional shortening z score were independently associated with an increased risk of death or transplantation.
There were no deaths among children with familial HCM in our study. However, familial HCM expressed 
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in childhood may not be entirely benign because some of these subjects may not have attained their maximal phenotypic expression yet and thus remain at continuing risk from arrhythmias and CHF.
Outcomes in Infants with HCM
Other series have found that HCM diagnosed in infancy carries a worse prognosis than when it is diagnosed in older age groups, with reported mortality varying widely but reaching ≈90% in some studies. 5, 7, 9, 19, 20 Better transplant-free survival for those children diagnosed with HCM at >1 compared with <1 year of age have been reported in the North American Pediatric Cardiomyopathy Registry cohort 5, 10 and an earlier analysis of the NACCS cohort. 4 Infants with HCM have a wider range of potential syndromic, mitochondrial, and metabolic etiologies, which may account for their consistently worse outcomes. In our study, short-term outcomes for infants tended to be worse despite the exclusion of children with metabolic and mitochondrial diseases, reflecting onset of a more severe disease process at a younger age. Although the proportion of children with death or transplantation in this youngest group was higher than for children diagnosed beyond the first year of life, long-term outcomes for those who survived the first year were comparable to those for older children ( Figure 2C ).
Sudden Cardiac Death
HCM resulting from sarcomere protein mutations is the most common genetically determined cardiovascular disease and a prominent cause of SCD in fit young adults. 21 SCD represents a continuing hazard for children with HCM 16 and was the most common mode of death encountered during late follow-up in our study. Identification of individual risk factors for SCD in children with HCM was beyond the scope of the present study but has recently been described for the overall NACCS cohort. 16 The use of ICDs was relatively common, with clinical decisions made by the treating physician. Appropriate ICD discharges were documented in 3 of 10 subjects for whom this information was available. Investigation of larger multicenter cohorts is ongoing to determine the precise incidence and risk fac- 
Study Limitations
The usual limitations of a retrospectively attained patient cohort are applicable to our study. Genetic testing was not uniformly available during the period of study enrollment, and therefore the genotype-outcome relationship is uncertain. Although our cohort represents the most consistently inclusive and complete longitudinal study of pediatric HCM, the small number of subjects and end point events limits statistical power and the feasibility of subgroup analysis. Some associations were clinically significant but not statistically significant, such as diagnosis in infancy (2-fold risk of death or transplant). Patients who received appropriate ICD discharges were included as survivors in our study, and thus our reported risk of death or transplantation may somewhat underrepresent the actual risk. The design of this study does not permit conclusions about the potential benefits of medical therapy or surgical myectomy, which were used frequently during subsequent follow-up.
CONCLUSIONS
The greatest risk of death or transplantation for children with HCM is in the first year after diagnosis, with 14% of study subjects achieving this combined end point by 1 year, compared with 0.4% per year thereafter. Independent risk factors for death or transplantation include symmetrical LV hypertrophy, Noonan syndrome, severity of LV free wall hypertrophy, and reduced LV systolic function. Deaths from CHF tend to occur soon after diagnosis, whereas the risk of sudden death is ongoing. The great majority of surviving subjects report no cardiac symptoms at latest follow-up. 
